Quick Take
Kaleido Biosciences (OTC:KLDO) intends to raise $100 million from the sale of its common stock, per an amended registration statement.
The company is developing microbiome-centric treatment candidates for hyperammonemia and other urea cycle disorders.
KLDO is seeking a high valuation for a very early stage firm with no existing investor support for the IPO.
Company & Technology
Lexington, MA-based Kaleido was founded in 2015 to develop therapeutic agents utilizing the body’s microbiome.
Management is headed by CEO Alison Lawton, who has been with the firm since December 2017 and was